Medical device regulation in Australia: safe and effective?
|
|
|
- Jessie Stevenson
- 10 years ago
- Views:
Transcription
1 Medical device regulation in Australia: safe and effective? Richard G McGee PGDipSurgAnat, MMed(ClinEpi), PhD Student Angela C Webster MMed(ClinEpi), PhD, Senior Lecturer Thomas E Rogerson BSc, MSc Student Jonathan C Craig MMed(ClinEpi), PhD, Professor Sydney School of Public Health, University of Sydney, Sydney, NSW. richard.mcgee@ sydney.edu.au MJA 2012; 196: doi: /mja Medical devices are ubiquitous in health care and have the potential to create large-scale health gains, but also unintended harms through device failure. In the United States in 2006, medical devices were responsible for 2712 deaths. 1 The recall of DePuy Orthopaedics articular surface replacement hip prosthesis (Warsaw, Ind, USA) helped to highlight deficiencies in medical device regulation worldwide. 2,3 Subsequent investigations in the US showed that most high-risk medical devices were being approved through processes that were not designed to assess safety or efficacy. 4 Investigations into medical device regulatory processes in Europe were hampered by a lack of transparency and accountability. 1 Medical device regulation is a complex and evolving area. Recently, a range of reports and reform proposals relevant to the Australian Therapeutic Goods Administration (TGA) have been put forward. A health technology assessment (HTA) tabled by the Department of Health and Ageing in December 2009 addressed the regulatory burden on business that results from HTA processes. 5 After a consultation period, the TGA responded to this report in September 2011 by setting out proposals to reclassify jointreplacement implants, amend the manner in which devices are included on the Australian Register of Therapeutic Goods (ARTG) and increase the availability of device product information on the TGA website. 6 In July 2011, the Department of Health and Ageing released a review that sought to increase the transparency of the TGA by improving communication in areas such as market authorisation processes and post-market The Medical Journal monitoring of Australia and ISSN: compliance, and 729X 5 March 2012 through raising stakeholder involvement The Medical Journal in the of TGA. Australia Subsequently, in Research November 2011, the Senate Standing Editorial p 222 Committees on Community Affairs Perspective p 232 released a report into the regulatory Letter p 240 standards for the approval of medical Research p 250 devices in Australia, which made Abstract Objective: To describe the frequency, characteristics and outcomes of reports of possible harms related to medical devices submitted to the Australian Therapeutic Goods Administration (TGA) using data made publicly available on the TGA website. Design and setting: A retrospective analysis, conducted in January 2012, of data made publicly available on the TGA website from January 2000 to December Main outcome measures: The number and nature of reports of medical device incidents, recalls and alerts. Results: Up to December 2011, 6812 incidents involving medical devices were reported to the TGA, although there were several periods where data were unavailable. Incidents were reported more frequently in later years, most often by device sponsors, and were often attributed to mechanical problems. 295 deaths and 2357 serious injuries have been related to incidents, with serious injury (597) highest in Most incidents involving medical devices were not investigated (47.5%), or, after investigation, no further action was taken (25.0%). During the same time period, there were 35 medical device recalls and 34 medical device alerts issued by the TGA, with no consistent increase over time. Conclusions: Despite TGA reform proposals, greater transparency is still needed. Issues that have not been addressed include patchy and conflicting data in the public domain and lack of explanations for the large proportion of uninvestigated reports. To maintain public confidence in the national regulatory system these problems need to be resolved. reference to most of the previous reports. 8 In addition, this report made further recommendations related to the recalled DePuy Orthopaedics articular surface replacement hip prosthesis, inducements paid by device companies to clinicians, improved reporting of adverse events by clinicians and the importation of medical devices over the internet, among others. 8 Finally, in December 2011, the TGA issued a document outlining their proposed changes in response to these reports, of which some changes related to medical devices. 9 We aimed to investigate the frequency, characteristics and outcomes of reports of possible harms related to medical devices, from the Australian perspective, using data made publicly available on the TGA website. Methods Data sources We only used publicly available sources of data that is, information provided by the ARTG ( PublicWeb.nsf/cuDevices?OpenView [accessed 7 Jun 2011]) and information about medical device incidents that was provided on the TGA website ( [accessed 24 Jan 2012]). Hence, ethics approval was not required for this study. We did not use information contained in medical device bulletins because they are not publicly accessible (only Australian health professionals currently working in a health care facility are allowed to subscribe to these after their application is approved by the TGA) and their use requires the permission of the TGA. All data extraction was conducted independently by R G M and T E R with consensus agreement. Number of medical devices The ARTG provides information on therapeutic goods that may legally be supplied in Australia. Each entry in the ARTG may provide information on one or more medical devices, with variants of a device included in a single entry. For example, two different-sized hip replacement prostheses may appear under the one entry. Each entry listed on the ARTG is classified by 256
2 1 Numbers of medical device recalls, alerts and incident reports,* January 2000 December 2011, and number of entries listing medical devices on the ARTG, All device recalls All device alerts Reports of medical device incidents ARTG entries ARTG = Australian Register of Therapeutic Goods. * From reports provided by the Therapeutic Goods Administration up until 24 January ARTG data only available for 2011 because of website design. Data incomplete or missing for these years. Each entry may include one or more variants of a device. manufacturers and the TGA into one of several risk categories based on a series of algorithms. 10 For example, low-risk devices include non-sterile dressings; low medium-risk devices include contact lenses; medium highrisk devices include infant incubators; and high-risk devices include permanent pacemakers. We used the ARTG website to determine the number and type of entries listed, which we used as a proxy for the number of medical devices available on the Australian market. However, because of the design of the ARTG website, with the potential for multiple devices within one entry, we were unable to count the true number of devices. Reports of medical device incidents If a problem occurs with a medical device, it may be reported to the TGA. The TGA website provides information on the frequency and characteristics of incident reports related to medical devices. We analysed all publicly available data on incidents involving medical devices from January 2000 to December 2011 to determine the number, sources, causes, and reported effects of such incidents. Response of the TGA to reports of medical device incidents Every report submitted to the TGA receives a risk analysis and is discussed by a panel of technical and clinical professionals. The TGA may decide that further investigation is not necessary at that time, or, after investigation, they may decide that no further action is necessary. Incidents that are not likely to lead to injury or a detrimental effect to patients or operators are not routinely investigated. On the other hand, if a medical device needs to be removed from the Australian market for reasons related to quality, efficacy or safety, the TGA will issue a device recall. If the TGA wishes to provide information or recommendations about a device, such as the outcome of an investigation, a medical device alert may be issued, which does not necessarily indicate that a product is unsafe. We analysed all publicly available data from January 2000 to December 2011 to determine the outcome of investigations into incidents involving medical devices. Results Number of medical devices There were entries for medical devices listed on the ARTG. Of these, most were low risk ( [48.5%]), (29.5%) were registered as low medium risk, 4981 (13.6%) were registered as medium high risk and 3059 (8.3%) were registered as high risk. From the available data, we were unable to determine how many entries were added per year or how many unsuccessful medical device applications had been made to the TGA. Reports of medical device incidents Data on incidents involving medical devices were unavailable for Jan 2000 Oct 2000, Jun 2002 Dec 2002, Jun 2003 Dec 2003, Jun 2004 Dec 2004 and Jul 2009 Dec In total, 6812 incidents were reported to the TGA and they have become more frequent over time (Box 1). It is unknown how many reports refer to the same medical device, as these data were not provided. There were 295 reported deaths related to incidents involving medical devices, 2357 incidents associated with serious injury, 1542 incidents associated with temporary injury and 2 Reported effects* of incidents involving medical devices, January 2000 December 2011 Number of reported effects No injury (n = 2616) Serious injury (n = 2357) Temporary injury (n = 1542) Death (n = 295) Report date * Total number adds to 6810 as two reports of incidents did not include the effect. From reports provided by the Therapeutic Goods Administration up until 24 January (Quarterly data.) Data unavailable for Jan 2000 Oct 2000, Jun 2002 Dec 2002, Jun 2003 Dec 2003, Jun 2004 Dec 2004 and Jul 2009 Dec
3 3 Most common sources of reports and reported causes for incidents involving medical devices,* January 2000 December Total 10 most common sources of incident reports Sponsor Nurse Hospital supply service Specialist Biomedical engineer Blood bank Medical administrator Overseas advice Patient or user Other most common causes of device incidents Unknown Mechanical Not device-related Component failure Electrical Manufacture Material or formulation deficiency Design Wear or deterioration Other * From reports provided by the Therapeutic Goods Administration up until 24 January Data incomplete or missing for these years. The source of incident reports was missing in 10 cases causes were reported for 6812 incidents incidents associated with no injury (Box 2). The number of serious injuries was highest in 2009 (597). Further information on what injuries were caused or how death occurred was unavailable on the website. The reported effect of the incident was not provided in two reports. Incidents were often attributed to more than one cause, as 7644 causes were reported for 6812 incidents. While the cause of incidents involving medical devices was most often reported as unknown, the second most commonly reported cause, mechanical (13.0%), sharply increased towards the end of the study period, representing 32.8% (316/962) of all reports in 2009 (Box 3). Medical device sponsors reported the most incidents (56.5%). The source of incident reports was missing in 10 cases. Response of TGA to reports of medical device incidents More than one outcome was often attributed to an incident, as there 4 Outcomes of TGA investigations of incidents involving medical devices,* January 2000 December 2011 Number of outcomes Not investigated (n = 3502) No further action (n = 1841) Product improvement (n = 447) User education (n = 325) Problem not confirmed (n = 272) Recall/hazard alert (n = 241) Other (n = 741) Report date TGA = Therapeutic Goods Administration. * From reports provided by the TGA up until 24 January (Quarterly data.) The panel has made a decision that further investigation of the particular event is not necessary at that time. Includes safety alerts, compliance testing, bulletin articles, referral to good manufacturing practice, company warnings and surveillance. Data unavailable for Jan 2000 Oct 2000, Jun 2002 Dec 2002, Jun 2003 Dec 2003, Jun 2004 Dec 2004 and Jul 2009 Dec
4 were 7369 outcomes for 6812 incidents. Most incident reports either were not investigated (47.5%), or were investigated but no further action was taken (25.0%). The proportion of incident reports not investigated increased in later years, from 41.1% (62/151) in 2000 to 59.5% (575/ 967) in Only 3.3% of reports resulted in a device recall or hazard alert, and 2.5% (187/7369) of reports in a safety alert being issued. The reported problem was unconfirmed for 3.7% of cases (Box 4). It is unknown how many incident reports were assigned more than one outcome, as these data were not provided. Thirty-five device recalls were issued by the TGA (Box 1). There was no consistent increase in the number of device recalls over time. Twelve of these recalls were considered high risk, as the device had the potential to be life-threatening or cause a serious risk to health. For example, Four Seasons Glow N Dark Condoms (Australian Therapeutic Supplies, Sydney, Australia) were recalled in 2003 because they failed to meet performance standards. Nineteen of these recalls were considered medium risk, as the device had the potential to cause illness or mistreatment. For example, INVACARE Action 2000 wheelchairs (Invacare Australia, Sydney, Australia) were recalled in 2009 because of a fault that could have caused occupants to fall from their wheelchair and sustain injury. Four of these recalls were considered low risk, as the device did not pose a significant hazard to health. For example, Dejour tampons (Dejour Sanitary Products, Melbourne, Australia) were recalled in 2003 for failing to meet mandatory absorbency requirements. Inconsistencies were found in the reported number of alerts issued by the TGA. An alphabetical list of all therapeutic alerts from January 2000 to December 2011 indicated there were 34 device-related alerts. The same list sorted by date indicated there were 33 device alerts issued. We cross-checked these lists, ensuring that each entry was only counted once, and found 34 unique device alerts (Box 1). Device alerts did not consistently increase over time. Discussion Based on publicly available data, reporting of incidents involving medical devices has become more frequent, but most reports are not investigated or, after investigation, no further action is taken. A problem was unconfirmed in only 3.7% of all cases; in comparison, there were only 35 medical device recalls and 34 medical device alerts issued by the TGA, with no apparent increase over time. Furthermore, publicly available data were often incomplete, inconsistent and insufficient to understand the assessment of the safety and efficacy of medical devices no data related to incidents were available since Despite a series of reports urging transparency and reform, our investigation highlights a number of problems. First, it is unclear why there are several periods where data on incidents involving medical devices were unavailable, particularly as the number of serious injuries related to incidents increased towards the end of In addition, the data provided on alerts were inconsistent. Second, if the proportion of device problems investigated but not subsequently confirmed remained relatively constant, it is unclear why a growing number of incident reports were not investigated. If these false alarms remain constant, this implies that there may have been some validity to the incident report in the remaining cases, although this cannot be determined because so many reports remain uninvestigated. It may be that these incidents were not likely to lead to injury and so were not investigated. Third, it is unclear what class of device is being recalled. Current product recalls describe the level of risk presented by an incident, but not by the device itself. Fourth, it is unclear why reports of medical device incidents are consistently increasing while device recalls are not. In total, 295 deaths related to device incidents were reported, yet, during a longer observational period, there were only 12 high-risk medical device recalls. Increasing reports may reflect an increased awareness of the need to report all adverse events among the community for example, through the establishment of the National Joint Replacement Registry. It may also reflect increased adherence of companies to their legal obligations, under sections 41MP and 41MPA of the Therapeutic Goods Act 1989 (Cwlth), to report all adverse events. 11 On the other hand, as the TGA website is updated and other proposals are implemented, some issues are likely to be resolved. For example, the TGA has now proposed a plan of action to reform the way in which medical devices are included in the ARTG. 9 From July 2012, all ARTG entries for medical devices will be required to include product name details. This will facilitate the generation of a list of all the medical devices available on the Australian market. In addition, there are proposals to provide greater levels of device product information on the TGA website. 9 While we have chosen to analyse data that are publicly available on the TGA website, this has led to a number of limitations. The data on medical device recalls, alerts and notifications are provided at a summary level, and so more advanced statistical analysis is not possible because data on individual devices are not provided. Because of the lack of up-to-date data, we were unable to determine whether the rise in the number of reported incidents involving medical devices was a random variation or the beginning of an increasing trend. In addition, we have not examined medical device bulletins or asked the TGA to provide further information. This is because we wanted to maintain the perspective of the average health care worker or informed consumer attempting to assess the safety and efficacy of a medical device. Finally, we could not locate data on the number of voluntary recalls issued by device manufacturers or the number of people affected by a recall because these data were not made public by the TGA. Clearly, the demands being placed on the TGA are changing over time and the TGA is responding to these changes. While our primary concerns centre around the transparency of available data, the various government reports and TGA proposals have sometimes focused on other important but different issues; for example, the reclassification of prosthetic 259
5 devices. None of the reports released to date or the reforms proposed by the TGA address the issues we have raised, namely missing and conflicting data, the increasing proportion of uninvestigated reports and a lack of information about the type of medical devices being recalled. The only reference to transparency in the Senate Standing Committees on Community Affairs report is the recommendation that the Government implements the recommendations of the Therapeutic Goods Administration Transparency Review in a timely manner. 8 Of the 21 recommendations contained in the Department of Health and Ageing review on the transparency of the TGA, none specifically mention medical devices and none address the issues we have raised here. Nevertheless, the TGA s recently released blueprint for reform does contain some constructive proposals for example, including more information about individual medical devices on the TGA website. These efforts will go some way towards increasing transparency and allowing the public to have access to information that will help them to make informed decisions about safety and effectiveness. In conclusion, medical devices are widely used to improve patient outcomes, but it is difficult to make informed decisions about the safety of any given device based on publicly available data from the TGA. Although recent government reports and reform proposals have gone some way towards improving the regulation of medical devices and the accountability of the TGA, greater transparency is still needed. Given the large number of deaths and serious injuries reportedly caused by device failures, this remains an issue of serious concern and further change is needed, so that public confidence in the regulatory system can be maintained. Competing interests: Jonathan Craig is a member of the Protocol Advisory Sub-committee of the Australian Medical Services Advisory Committee. Received 30 Sep 2011, accepted 13 Feb Heneghan C, Thompson M, Billingsley M, Cohen D. Medical-device recalls in the UK and the device-regulation process: retrospective review of safety notices and alerts. BMJ Open 2011; 1: e Cohen D. Out of joint: the story of the ASR. BMJ 2011; 342: d Graves SE. What is happening with hip replacement? Med J Aust 2011; 194: Zuckerman D, Brown P, Nissen S. Medical device recalls and the FDA approval process. Arch Intern Med 2011; 171: Australian Government Department of Health and Ageing. Review of health technology assessment in Australia, December Canberra: DoHA, gov.au/internet/main/publishing.nsf/content/ 00E847C9D69395B9CA25768F007F589A/ $File/hta-review-report.pdf 6 Therapeutic Goods Administration. Reforms to the medical devices regulatory framework. Proposals. Canberra: TGA, Panel to Review the Transparency of the Therapeutic Goods Administration. Review to improve the transparency of the Therapeutic Goods Administration. Final report, June Canberra: Commonwealth of Australia, Senate Standing Committees on Community Affairs. Inquiry into the regulatory standards for the approval of medical devices. Canberra: Parliament of Australia Senate, Committees/Senate_Committees?url=clac_ctte/ medical_devices/report/index.htm (accessed Feb 2012). 9 Therapeutic Goods Administration. TGA reforms: a blueprint for TGA s future. Canberra: TGA, tga-reforms htm 10 Australian Government Department of Health and Ageing Therapeutic Goods Administration. Australian regulatory guidelines for medical devices (ARGMD). Canberra: TGA, Therapeutic Goods Act 1989 (Cwlth) (as amended). C2011C00589/Html/Text#_Toc
Regulation Impact Statement CLINICAL REGISTERS FOR HIGH RISK IMPLANTABLE MEDICAL DEVICES
Regulation Impact Statement CLINICAL REGISTERS FOR HIGH RISK IMPLANTABLE MEDICAL DEVICES 18 February 2013 1. Introduction... 1 1.1 What is a high risk implantable medical device?... 1 2. The Problem...
PORTLAND ORTHOPAEDICS PTY LTD MARGRON TOTAL HIP REPLACEMENT PROCEDURE RECALL
Page 1 of 1 PORTLAND ORTHOPAEDICS PTY LTD MARGRON TOTAL HIP REPLACEMENT Suite 3 Level 5 St George Private Hospital 1 South Street KOGARAH NSW 2217 PROCEDURE RECALL This revision supersedes all previous
MTAA KEY POLICIES FOR 2013 ELECTION. 1 February 2013. 1. Improving reimbursement of medical technologies by private health insurance
MTAA KEY POLICIES FOR 2013 ELECTION 1 February 2013 1. Improving reimbursement of medical technologies by private health insurance Medical technology is not funded by the Commonwealth Government in the
We have carefully reviewed your questions and the recent promotion for your program on the ABC website.
23 May 2014 Mr P Cronau Senior Producer, Four Corners, The ABC, GPO Box 9994, Sydney NSW 2001. Dear Mr Cronau, We have carefully reviewed your questions and the recent promotion for your program on the
Clinical Trials - Insurance and Indemnity
Policy Directive Clinical Trials - Insurance and Indemnity Document Number PD2011_006 Publication date 25-Jan-2011 Functional Sub group Corporate Administration - Governance Clinical/ Patient Services
Guide to the National Safety and Quality Health Service Standards for health service organisation boards
Guide to the National Safety and Quality Health Service Standards for health service organisation boards April 2015 ISBN Print: 978-1-925224-10-8 Electronic: 978-1-925224-11-5 Suggested citation: Australian
Hazard Identification, Risk Assessment and Management Procedure. Documentation Control
Hazard Identification, Risk Assessment and Management Procedure Reference: Date approved: Approving Body: Implementation Date: Version: 3 Documentation Control GG/CM/007 Trust Board Supersedes: Version
ATSB RESEARCH AND ANALYSIS REPORT ROAD SAFETY. Characteristics of Fatal Road Crashes During National Holiday Periods
ATSB RESEARCH AND ANALYSIS REPORT ROAD SAFETY Characteristics of Fatal Road Crashes During National Holiday Periods July 2006 ATSB RESEARCH AND ANALYSIS REPORT ROAD SAFETY Characteristics of Fatal Road
WHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE
WHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE White paper produced by Maetrics For more information, please contact global sales +1 610 458 9312 +1 877 623 8742 [email protected]
INSURANCE BROKERS CODE OF PRACTICE
INSURANCE BROKERS CODE OF PRACTICE BUILDING PROFESSIONAL COMPETENCE AND CONSUMER CONFIDENCE The insurance broking profession is about helping you to navigate the unavoidable complexities of insurance products
Hip replacements: Getting it right first time
Report by the Comptroller and Auditor General NHS Executive Hip replacements: Getting it right first time Ordered by the House of Commons to be printed 17 April 2000 LONDON: The Stationery Office 0.00
RECALLS in EUROPE. Past, present, near & further future. Gert Bos BSI Medcon May 2012
RECALLS in EUROPE Past, present, near & further future Gert Bos BSI Medcon May 2012 A C P D Vigilance, vigilant: Continually watchful or on guard; always prepared for possible danger Content 2 Current
Accreditation Workbook for Mental Health Services. March 2014
Accreditation Workbook for Mental Health Services March 2014 Accreditation Workbook for Mental Health Services, 2014 ISBN Print: 978-1-921983-66-5 ISBN Online: 978-1-921983-60-3 Commonwealth of Australia
NATIONAL INSURANCE BROKERS ASSOCIATION OF AUSTRALIA (NIBA) Submission to WorkCover Western Australia. Legislative Review 2013
NATIONAL INSURANCE BROKERS ASSOCIATION OF AUSTRALIA (NIBA) ABOUT NIBA Submission to WorkCover Western Australia Legislative Review 2013 February 2014 NIBA is the peak body of the insurance broking profession
Insurance Insights. When markets hit motorists. How international financial markets impact Compulsory Third Party insurance
Insurance Insights When markets hit motorists How international financial markets impact Compulsory Third Party insurance August 2012 Chris McHugh Executive General Manager Statutory Portfolio Commercial
University of New England Compliance Management Framework and Procedures
University of New England Compliance Management Framework and Procedures Document data: Document type: Administering entity: Framework and Procedures Audit and Risk Directorate Records management system
AUSTRALIAN REGULATORY GUIDELINES FOR MEDICAL DEVICES
AUSTRALIAN REGULATORY GUIDELINES FOR MEDICAL DEVICES Version 1.0 April 2010 Version history Version Description of change Author Effective Date 1.0 Initial publication on TGA website ODBT 28 April 2010
TGA key performance indicators and reporting measures
TGA key indicators and reporting measures Regulator Performance Framework Version 1.0, May 2015 About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the
INSURANCE BROKERS CODE OF PRACTICE
INSURANCE BROKERS CODE OF PRACTICE INSURANCE BROKERS CODE OF PRACTICE OVERVIEW 4-5 IMPORTANT BACKGROUND INFORMATION What does the Code do for you? (Code Objectives) How to navigate the Code How up to date
Australian Reimbursement
Australian Reimbursement The true costs (and benefits) of market entry Hosted by Brandwood Biomedical 21 April 2015 +61 2 9906 2984 [email protected] www.brandwoodbiomedical.com BRANDWOOD:BIOMEDICAL
Standard 5. Patient Identification and Procedure Matching. Safety and Quality Improvement Guide
Standard 5 Patient Identification and Procedure Matching Safety and Quality Improvement Guide 5 5 5October 5 2012 ISBN: Print: 978-1-921983-35-1 Electronic: 978-1-921983-36-8 Suggested citation: Australian
ACS CLOUD COMPUTING CONSUMER PROTOCOL. Response from AIIA
ACS CLOUD COMPUTING CONSUMER PROTOCOL Response from AIIA AUGUST 2013 INTRODUCTION The Australian Information Industry Association (AIIA) is the peak national body representing multinational and domestic
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
Answers to commonly asked questions from patients with metal-on-metal hip replacements / resurfacings. Contents
Answers to commonly asked questions from patients with metal-on-metal hip replacements / resurfacings John Skinner 1 and Alister Hart 2, Consultant Orthopaedic Surgeons and Directors of the London Implant
INQUIRY INTO TICKET SCALPING IN AUSTRALIA Senate Economics References Committee
10 February 2014 Senate Standing Committees on Economics PO Box 6100 Parliament House CANBERRA ACT 2600 INQUIRY INTO TICKET SCALPING IN AUSTRALIA Senate Economics References Committee Live Performance
G. Recalls. http://www.fda.gov/safety/recalls/industryguidance/ucm129259.htm.
G. Recalls 1. Background When an FDA-regulated product is defective, potentially harmful, or mislabeled, recalling that product removing it from the market or correcting the problem is often the most effective
Clinical Trials Jurisdictional Working Group: Update
ACTA International Clinical Trials Symposium Clinical Trials Jurisdictional Working Group: Update James Cokayne Principal Policy Officer, Research Ethics and Governance Unit NSW Office for Health and Medical
Important changes to insurance
Important changes to insurance Effective 1 July 2013 rest.com.au 1800 063 627 Contents Why have these changes been made? 2 New cover levels 2 New insurance costs 5 Access to higher cover under the new
Actuaries Institute submission to the Private Health Insurance Review
7 December 2015 The Hon Sussan Ley MP Minister for Health Parliament House CANBERRA ACT 2600 Email: [email protected] Dear Minister Actuaries Institute submission to the Private Health
A Guide to Pharmacy Documentation For Clinical Trials
A Guide to Pharmacy Documentation For Clinical Trials Roy Sinclair Clinical Trials Pharmacist St. George s Hospital (to Sep 2007) Lecturer Kingston University January 2008 A Guide to Pharmacy Documentation
LIWMPC Life Insurance Industry Update. Adam Norman & David Millar
LIWMPC Life Insurance Industry Update Adam Norman & David Millar This presentation has been prepared for the Actuaries Institute 2014 Financial Services Forum. The Institute Council wishes it to be understood
Australian Charities and Not-for-profits Commission: Regulatory Approach Statement
Australian Charities and Not-for-profits Commission: Regulatory Approach Statement This statement sets out the regulatory approach of the Australian Charities and Not-for-profits Commission (ACNC). It
The characteristics of fatal road accidents during the end of year festive period
The characteristics of fatal road accidents during the end of year festive period 1994-2003 March 2004 Traffic Management and Road Safety Unit Ministry of Public Infrastructure, Land Transport and Shipping
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
AN ANALYSIS OF ELECTRONIC HEALTH RECORD-RELATED PATIENT SAFETY CONCERNS
AN ANALYSIS OF ELECTRONIC HEALTH RECORD-RELATED PATIENT SAFETY CONCERNS 1 HARDEEP SINGH, MD, MPH MICHAEL E. DEBAKEY VA MEDICAL CENTER BAYLOR COLLEGE OF MEDICINE DEAN SITTIG, PHD UNIVERSITY OF TEXAS HEALTH
ANNEXES. Medical device approval process. Annex II IMB safety notice, 27 August 2010. Annex III IMB ASR press statement.
IRISH MEDICINES BOARD OIREACHTAS JOINT COMMITTEE ON HEALTH & CHILDREN DEPUY ASR (TM) ARTICULAR SURFACE REPLACEMENT AND ASR (TM) XL ACETABULAR SYSTEM 19 JULY 2012 ANNEXES Annex I Medical device approval
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007
DATE APPROVED: DATE EFFECTIVE: Date of Approval. REFERENCE NO. MOH/04 PAGE: 1 of 7
SOURCE: Ministry of Health DATE APPROVED: DATE EFFECTIVE: Date of Approval REPLACESPOLICY DATED: 1 POLICY TITLE: Incident/Accident Reporting REFERENCE NO. MOH/04 PAGE: 1 of 7 REVISION DATE(s): Ministry
Standard 1. Governance for Safety and Quality in Health Service Organisations. Safety and Quality Improvement Guide
Standard 1 Governance for Safety and Quality in Health Service Organisations Safety and Quality Improvement Guide 1 1 1October 1 2012 ISBN: Print: 978-1-921983-27-6 Electronic: 978-1-921983-28-3 Suggested
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
Employers Liability Registers
Employers Liability Registers Working in partnership with you to perform an independent audit to meet the FSA s requirements on What are the FSA employers liability requirements? The FSA published updated
Risk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
Process for advising on the feasibility of implementing a patient access scheme
Process for advising on the feasibility of implementing a patient access scheme INTERIM September 2009 Patient Access Schemes Liaison Unit at NICE P001_PASLU_Process_Guide_V1.3 Page 1 of 21 Contents (to
Risk and Quality Management Program Self-Assessment
The Risk and Quality Management Program tool has been developed to assist providers to assess their internal Risk and Quality Management programs. The self-assessment is organized according to the major
Australian Safety and Quality Framework for Health Care
Activities for MANAGERS Australian Safety and Quality Framework for Health Care Putting the Framework into action: Getting started Contents Principle: Consumer centred Area for action: 1.1 Develop methods
Management of Business Support Service Contracts
The Auditor-General Audit Report No.37 2004 05 Business Support Process Audit Management of Business Support Service Contracts Australian National Audit Office Commonwealth of Australia 2005 ISSN 1036
Health reform, ECLIPSE and data management in the private sector
Health reform, and data management in the private sector Nicolle Predl Abstract The Australian Health Service Alliance (AHSA) is a company that provides services to more than twenty private health insurers,
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
The fourth hurdle system. International HTA agencies. Australian PBAC. Difference between health technology regulatory body and HTA body
* This presentation is prepared by the author in one s personal capacity for the purpose of academic exchange and does not represent the views of his/her organisations on the topic discussed. Local Application
Translating Evidence to Safer Care Patient Safety Research Introductory Course Session 7 Albert W Wu, MD, MPH Former Senior Adviser, WHO Professor of Health Policy & Management, Johns Hopkins Bloomberg
Plumbing and Drainage Regulation 2012
Regulatory Impact Statement Subordinate Legislation Act 1989 Plumbing and Drainage Regulation 2012 A regulation under the Plumbing and Drainage Act 2011 April 2012 Enquiries to: NSW Fair Trading Policy
Application instructions
Application instructions Conformity assessment certification Version 1.4, April 2015 About the Therapeutic Goods Administration (TGA) The Therapeutic Goods Administration (TGA) is part of the Australian
Medicinal Cannabis in Queensland. It s Past Midnight in the Garden of Good and Evil!
Medicinal Cannabis in Queensland It s Past Midnight in the Garden of Good and Evil! Contact Dr Sue Ballantyne, Director, Medicines Regulation And Quality (MRQ) [email protected] Greg Perry or Will
Disclosure and Investor Communications Policy
CONTENTS OVERVIEW...2 Purpose...2 Who the policy applies to...2 Rationale...2 Related information...3 DETAILED INFORMATION...3 Type of information that needs disclosure...3 Disclosure Officer...5 Role
FDA Presentation - Society for Clinical Research Sites
FDA Presentation - Society for Clinical Research Sites FDA Presentation - Dr. Richard Moscicki, MD FDA CDER Deputy Director for Clinical Research Sites Faculty Disclosure In compliance with ACCME Guidelines,
WORKING IN ISOLATION PROCEDURE
Document uncontrolled when printed Procedure ID no 0479/05 WORKING IN ISOLATION PROCEDURE This procedure is applicable to: All Department of Education and Children's Services employees. DOCUMENT CONTROL
For Employees: Employees: What What to to do do when when an an accident occurs 08/19/14/dmv
For Employees: What to do when an accident occurs 08/19/14/dmv When there is a work-related accident or illness, procedures must be taken to ensure the employees needs are met with respect to treatment
The performance of the Australian Securities and Investments Commission Submission 202
28 October 2013 The Manager Senate Standing Committees on Economics PO Box 6100 Parliament House Canberra ACT 2600 [email protected] Dear Sir The performance of ASIC The Insolvency Practitioners
GAO ADVERSE EVENTS. Surveillance Systems for Adverse Events and Medical Errors. Testimony
GAO For Release on Delivery Expected at 10:30 a.m. Wednesday, February 9, 2000 United States General Accounting Office Testimony Before the Subcommittees on Health and Environment, and Oversight and Investigations,
13 ENVIRONMENTAL AND SOCIAL MANAGEMENT SYSTEM
13 ENVIRONMENTAL AND SOCIAL MANAGEMENT SYSTEM This ESIA has identified impacts (both positive and negative) to the physical, natural and socio-economic environments, as well as to community and worker
P/T 2B: 2 nd Half of Term (8 weeks) Start: 26-AUG-2013 End: 20-OCT-2013 Start: 21-OCT-2013 End: 15-DEC-2013
2013-2014 SPECIAL TERM ACADEMIC CALENDAR FOR SCRANTON EDUCATION ONLINE (SEOL), MBA ONLINE, HUMAN RESOURCES ONLINE, NURSE ANESTHESIA and ERP PROGRAMS SPECIAL FALL 2013 TERM Key: P/T = Part of Term P/T Description
P/T 2B: 2 nd Half of Term (8 weeks) Start: 25-AUG-2014 End: 19-OCT-2014 Start: 20-OCT-2014 End: 14-DEC-2014
2014-2015 SPECIAL TERM ACADEMIC CALENDAR FOR SCRANTON EDUCATION ONLINE (SEOL), MBA ONLINE, HUMAN RESOURCES ONLINE, NURSE ANESTHESIA and ERP PROGRAMS SPECIAL FALL 2014 TERM Key: P/T = Part of Term P/T Description
How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters
environmental failure analysis & prevention health technology development How to Use the Design Process to Manage Risk: Elements of Design Controls and Why It Matters Kevin L. Ong, Ph.D., P.E. Managing
Direct Source Procurement
The Auditor-General Audit Report No.11 2010 11 Performance Audit Australian National Audit Office Commonwealth of Australia 2010 ISSN 1036 7632 ISBN 0 642 81155 5 COPYRIGHT INFORMATION This work is copyright.
P/T 2B: 2 nd Half of Term (8 weeks) Start: 24-AUG-2015 End: 18-OCT-2015 Start: 19-OCT-2015 End: 13-DEC-2015
2015-2016 SPECIAL TERM ACADEMIC CALENDAR For Scranton Education Online (SEOL), Masters of Business Administration Online, Masters of Accountancy Online, Health Administration Online, Health Informatics
JOB AND PERSON SPECIFICATION
Adelaide Health Service LYELL McEWIN HOSPITAL JOB AND PERSON SPECIFICATION Position Title: Advanced Nurse /Midwife Nurse Practitioner Perinatal Mental Health Classification Code: Registered Nurse/Midwife
Managing Medicines Access Programs. Guiding principles for the governance of Medicines Access Programs in Australian hospitals
Managing Medicines Access Programs Guiding principles for the governance of Medicines Access Programs in Australian hospitals May 2015 Council of Australian Therapeutic Advisory Groups Address: c/ - NSW
Risk Management of GMP Audits in Australia. Tony Gould Chief Auditor Office of Manufacturing Quality
Risk Management of GMP Audits in Australia Tony Gould Chief Auditor Office of Manufacturing Quality ICDRA, Berne September 2008 Topics General risk management of audits Risk approach to audit scheduling
Accounting and Auditing Matters
Accounting and Auditing Matters The Chief Accountant is the principal adviser to the Commission on accounting and auditing matters arising from the administration of the federal securities laws. Activities
executive summary Scope Aim and targeted readership
executive summary Scope The development, evaluation and introduction of medical innovations and technologies in general and innovative medical devices in particular are considered an increasingly important
Chapter 3. High revision rates: the consumer experience
Introduction Chapter 3 High revision rates: the consumer experience 3.1 The previous chapter focussed on the role of the TGA in regulating the quality of medical devices in Australia. This examined both
